Baseline values | Whole cohort | PAH | PAH with comorbidities | |||
---|---|---|---|---|---|---|
Cox regression | n | Cox regression | n | Cox regression | n | |
p-value | p-value | p-value | ||||
Survival | ||||||
 6MWD | < 0.0001 | 137 | 0.006 | 65 | 0.052 | 42 |
 NT-proBNP | 0.006 | 102 | 0.011 | 63 | 0.356 | 37 |
 WHO-FC | 0.005* | 121 | 0.001* | 74 | 0.403 | 46 |
 RA area | 0.254 | 133 | 0.991 | 82 | 0.472 | 49 |
 RV area | 0.778 | 135 | 0.631 | 84 | 0.505 | 49 |
 TAPSE | 0.006 | 137 | 0.033 | 86 | 0.220 | 49 |
 LV-EI | 0.613 | 111 | 0.896 | 72 | 0.282 | 38 |
 RV pump function | < 0.0001 | 109 | < 0.0001 | 85 | 0.499 | 49 |
Time to clinical worsening | ||||||
 6MWD | < 0.0001* | 109 | 0.02 | 65 | 0.047* | 44 |
 NT-proBNP | 0.024 | 102 | 0.07 | 63 | 0.485 | 39 |
 WHO-FC | 0.001 | 122 | < 0.0001* | 74 | 0.346 | 48 |
 RA area | 0.002 | 133 | 0.067 | 82 | 0.074 | 51 |
 RV area | 0.017 | 135 | 0.073 | 84 | 0.342 | 51 |
 TAPSE | 0.049 | 137 | 0.071 | 86 | 0.679 | 51 |
 LV-EI | 0.096 | 111 | 0.398 | 72 | 0.065 | 39 |
 RV pump function | < 0.0001* | 135 | < 0.0001 | 84 | 0.344 | 51 |